miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer
AbstractTriple negative breast cancer (TNBC) is characterised by the lack of receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2). Since it cannot be treated by current endocrine therapies which target these receptors and due to its aggressive nature, it has one of the worst prognoses of all breast cancer subtypes. The only treatments remain chemo- and/or radio-therapy and surgery and because of this, novel biomarkers or treatment targets are urgently required to improve disease outcomes. MicroRNAs represent an attractive candidate for targeted therapies against TNBC, due to their natural ability to act as antisense interactors and regulators of entire gene sets involved in malignancy and their superiority over mRNA profiling to accurately classify disease. Here we review the current knowledge regarding miRNAs as biomarkers in TNBC and their potential use as therapeutic targets in this disease. Further, we review other epigenetic changes and interactions of these changes with microRNAs in this breast cancer subtype, which may lead to the discovery of new treatment targets for TNBC. View Full-Text
Share & Cite This Article
Mathe, A.; Scott, R.J.; Avery-Kiejda, K.A. miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. Int. J. Mol. Sci. 2015, 16, 28347-28376.
Mathe A, Scott RJ, Avery-Kiejda KA. miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. International Journal of Molecular Sciences. 2015; 16(12):28347-28376.Chicago/Turabian Style
Mathe, Andrea; Scott, Rodney J.; Avery-Kiejda, Kelly A. 2015. "miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer." Int. J. Mol. Sci. 16, no. 12: 28347-28376.